Repository logo
 
Publication

Central Diabetes Insipidus Following Immunization With BNT162b2 mRNA COVID-19 Vaccine: a Case Report

2022Journal article Open access
Simple item page
dc.contributor.authorBouça, B
dc.contributor.authorRoldão, M
dc.contributor.authorBogalho, P
dc.contributor.authorCerqueira, L
dc.contributor.authorSilva-Nunes, J
dc.date.accessioned2022-12-21T15:48:00Z
dc.date.available2022-12-21T15:48:00Z
dc.date.issued2022
dc.description.abstractIntroduction: Cases of central diabetes insipidus (CDI) have been reported after COVID-19 infection, with hypophysitis being the most likely cause. COVID-19 vaccines potential adverse effects may mimetize some of these complications. Case report: Woman 37 years old, with rheumatoid arthritis under adalimumab (40 mg twice a month) since December 2018. She was in her usual state of health when she has received the second dose of BNT162b2 mRNA COVID-19 vaccine (June 2021). Seven days later, she started reporting intense thirst and polyuria and consulted her family physician. Blood analysis: creatinine 0.7 mg/dL, glucose 95mg/dL, Na+ 141mEq/L, K+ 3.9 mEq/L, TSH 3.8 mcUI/L (0.38-5.33), FT4 0.9 ng/dL (0.6-1.1), cortisol 215.4 nmol/L (185-624), ACTH 21.9 pg/mL (6- 48), FSH 4.76 UI/L, LH5.62 UI/L, estradiol 323 pmol/L, IGF1 74.8 ng/mL (88-209), PRL 24.7mcg/L (3.3-26.7) osmolality 298.2 mOs/Kg (250- 325); Urine analysis: volume 10200 mL/24h, osmolality 75 mOs/Kg (300-900), density 1.002. On water restriction test: 0' - Serum osmolality 308.8mOsm/Kg vs. urine osmolality 61.0 mOsm/Kg; 60' - urine osmolality 102 mOsm/Kg; urine osmolality 1 h after desmopressine was 511mOsm/kg. MRI revealed no abnormal signs consistent with hypophysitis except for the loss of the posterior pituitary bright spot on T1 weighted imaging. Diagnosis of CDI was assumed, and started therapy with desmopressine. A report of potential adverse effect was addressed to national health authorities. Conclusion: In hypophysitis MRI often shows loss of posterior pituitary bright spot on T1 weighted imaging, pituitary enlargement or stalk thickening but those findings were not present in this patient. To the best of our knowledge, CDI has never been reported following administration of a COVID-19 vaccine.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationFront Endocrinol (Lausanne) . 2022 May 4;13:889074.pt_PT
dc.identifier.doi10.3389/fendo.2022.889074.pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.17/4311
dc.language.isoengpt_PT
dc.publisherFrontiers Media SApt_PT
dc.subjectHCC ENDpt_PT
dc.subjectHSJ NRADpt_PT
dc.subjectAdultpt_PT
dc.subjectFemalept_PT
dc.subjectHumanspt_PT
dc.subjectBNT162 Vaccinept_PT
dc.subjectCOVID-19 Vaccines / adverse effectspt_PT
dc.subjectCOVID-19* / prevention & controlpt_PT
dc.subjectDiabetes Insipidus, Neurogenic* / complicationspt_PT
dc.subjectDiabetes Insipidus, Neurogenic* / etiologypt_PT
dc.subjectDiabetes Mellitus*pt_PT
dc.subjectHypophysitis* / complicationspt_PT
dc.subjectImmunization / adverse effectspt_PT
dc.subjectRNA, Messengerpt_PT
dc.titleCentral Diabetes Insipidus Following Immunization With BNT162b2 mRNA COVID-19 Vaccine: a Case Reportpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.startPage889074pt_PT
oaire.citation.titleFrontiers in Endocrinologypt_PT
oaire.citation.volume13pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Frontiers Endocrinol 2022.pdf
Size:
878.37 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

END - Artigos
NRAD - Artigos